Sign In
Search Icon
Menu Icon
 
 

FY 2025 President’s Request: ASPR Highlights

The FY 2025 President’s Budget discretionary request for ASPR is $3.8 billion, which is an increase of +$138 million above FY 2023. The budget also proposes $20 billion in mandatory funding across HHS public health agencies to strengthen the nation’s biodefense capabilities, of which $10.54 billion would support ASPR activities.

Budget Summary
(Dollars in Millions)

 

FY 2023
Final

FY 2024
CR

FY 2025
President’s Budget

FY 2025 +/- FY 2023

Budget Authority

3,629.677

3,629.677

3,768.088

+138.411

Program Level

3,629.677

3,629.677

3,768.088

+138.411

Mandatory Pandemic Preparedness (non-add)

-

-

10,540.000

+10,540.000

FTE

1,246

1,270

1,463

+217


Key Proposed Changes

Throughout the pandemic, the Industrial Base Management and Supply Chain office supported $17 billion of investments in expanding the domestic industrial base and other critical manufacturing contracts, in addition to critical investments made by the Biomedical Advanced Research and Development Authority and other ASPR components. The President’s Budget ensures ASPR can continue its efforts to strengthen the domestic medical supply chain. The Budget includes $95 million to expand and accelerate development and domestic production of medical countermeasures and improve visibility and management of medical supply chains to mitigate potential shortages of priority drugs and devices.  Specifically, the President’s Budget provides $75 million to onshore production of medical countermeasures (MCMs) and active pharmaceutical ingredients, consistent with Made in America and National Biodefense Strategy goals. The Budget also includes $20 million to expand end-to-end visibility and management of the medical and public health supply chain for priority drugs and devices.

Vaccine Manufacturing c